NOW FDA APPROVED

See our press release

© 2025 Abeona Therapeutics Inc. All rights reserved. US-COM-ZEV-250033 03/25

Contact Us Careers
Facebook Twitter LinkedIn
logo_abeona_retina
  • Home
  • About
    • Mission
    • Leaders
  • Products
  • Science
    • Pipeline
    • Manufacturing
    • The AIMTM Vector
  • Clinical Trials
    • Overview
  • Access Policy
  • Investors & Media
    • Overview
    • News / Events
    • Company Information
    • Financial Information
    • Stock Data
    • SEC Filings
    • Corporate Governance
  • Contact Us
  • Careers
×
  • Home
  • About
    • Mission
    • Leaders
  • Products
  • Science
    • Pipeline
    • Manufacturing
    • The AIMTM Vector
  • Clinical Trials
    • Overview
  • Access Policy
  • Investors & Media
    • Overview
    • News / Events
    • Company Information
    • Financial Information
    • Stock Data
    • SEC Filings
    • Corporate Governance
  • Contact Us
  • Careers

Press Releases

Investors

Investors & Media

  • Overview
  • News / Events
    • Overview
    • Press Releases
    • Events
    • Email Alerts
  • Company Info
    • Overview
    • Profile
    • Presentations
    • Management Team
    • Scientific Advisory Board
    • Contacts
  • Financial Info
    • Overview
    • Financial Results
  • Stock Data
    • Overview
    • Quote
    • Charts
    • Historical Data
  • SEC Filings
    • Overview
    • All SEC Filings
    • Annual Reports
    • Quarterly Reports
    • Section 16 Filings
  • Governance
    • Overview
    • Board of Directors
    • Board Committees
    • Governance Documents
  • Investor Tools
    • Email Alerts
    • Tear Sheet
    • Contacts
    • RSS News Feed
  • News / Events

  • Overview
  • Press Releases
  • Events
  • Email Alerts

Abeona Reports Update from EB-101 Gene Therapy in Epidermolysis Bullosa at 21st Annual ASGCT Meeting

May 17, 2018

Abeona Therapeutics Announces Appointment of Stefano Buono and Richard Van Duyne to its Board of Directors

May 14, 2018

Abeona Therapeutics Reports First Quarter 2018 Financial Results and Business Highlights

May 11, 2018

Abeona Therapeutics Announces Upcoming Presentations

May 8, 2018

Abeona Announces FDA Grants RMAT Designation to ABO-102 Gene Therapy in MPS IIIA

Apr 23, 2018

Abeona Therapeutics Receives Orphan Drug Designation in the European Union for ABO-202 Gene Therapy Program in Batten Disease

Apr 20, 2018

Abeona Therapeutics Appoints Carsten Thiel, Ph.D., as Chief Executive Officer

Apr 2, 2018

Abeona Therapeutics Reports Fourth Quarter 2017 Financial Results and Business Highlights

Mar 16, 2018

Abeona Therapeutics Receives FDA Rare Pediatric Disease Designation for ABO-202 Gene Therapy Program in CLN1 Disease

Mar 15, 2018

Abeona Therapeutics Announces Upcoming Conference Participation

Feb 21, 2018
RSS
    • 1...
    • 14
    • 15
    • 16
    • 17
    • 18
    • 19
    • 20
    • 21
    • 22
    • 23
    • ...31

    © 2025 Abeona Therapeutics Inc. All Rights Reserved. | Privacy Policy Terms of Use